Clinical Trial Update: Seroma and Hematoma Rates: MAXIGESIC IV vs. Ketorolac in Breast Cancer Surgery

View source ↗

Summary

A clinical trial comparing MAXIGESIC IV to Ketorolac in breast cancer surgery, focusing on seroma and hematoma rates; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Ketorolac (Ketorolac tromethamine)
• MAXIGESIC IV

Snippet

Sponsor: Seoul National University Hospital | Conditions: Breast Cancer, Post-Operative Hematoma | Status: NOT_YET_RECRUITING